As a group, cardiovascular diseases constitute the leading cause of death and hospitalization in Western countries in general and especially in Spain. The Cardiovascular Diseases program focuses on the study of heart failure and vascular pathology. In particular, we pay special attention to arterial hypertension (one of the main factors involved in the development of heart failure), atherothrombosis and atrial fibrillation (the underlying process behind the development of ischemic events in the brain and heart).
Program research focuses on::
Understanding the mechanisms through which the ventricular myocardium, atrial endocardium and arterial wall are damaged in processes involving heart failure, atrial fibrillation and stroke.
Developing blood markers that help with early detection of the lesions caused by these mechanisms and that have diagnostic and preventive uses in these processes.
Identifying new therapeutic targets related to the mechanisms involved and designing new drugs for more effective treatment of heart failure and ischemic events of the brain and heart.
The multidisciplinary research team is made up of specialists in both clinical and basic research. We also have experimental models covering a full range of needs (including in vitro models, in silico models for chemical modeling and in vivo animal models). Our program projects are developed with a clear translational approach because they are implemented in close collaboration with the Departments of Cardiology and Cardiac Surgery, Hematology and Internal Medicine at the Clínica Universidad de Navarra, as well as CIMA's own Translational Development Program.
The program currently forms part of the Cardiovascular Research Network (RIC) financed by the Instituto de Salud Carlos III and participates in several multinational research consortia as part of the European Union's Seventh Framework Program (FP7). It also works on joint research projects with academic centers and biotech and pharmaceutical companies in Spain, other European countries and the United States.